BGC
PNT

Beutel, Goodman & Co’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Beutel, Goodman & Co’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,174
Closed -$64K – 78
2023
Q2 		$64K Buy
+7,174
New +$63.3K ﹤0.01% 71

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Beutel, Goodman & Co's PNT Position: Q3 2023 in Review

Beutel, Goodman & Co sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q3 2023, closing a stake of 7,174 shares — an estimated $64K sold.

Beutel, Goodman & Co first reported a position in PNT in Q2 2023 and held it in 1 quarter. The position peaked at $64K in Q2 2023. 125 funds tracked by Wall St. Rank hold PNT as of Q3 2023.

  • Beutel, Goodman & Co reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Beutel, Goodman & Co sold 7,174 POINT Biopharma Global Inc. Common Stock shares in Q3 2023, an estimated $64K.
  • Beutel, Goodman & Co first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Beutel, Goodman & Co's POINT Biopharma Global Inc. Common Stock position peaked at $64K in Q2 2023.
  • 125 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q3 2023.

Based on Beutel, Goodman & Co's 13F filing for Q3 2023, filed 13 Nov 2023.